About Met-Enkephalin
Binds OGF receptors (zeta opioid receptors) on cell nuclei, regulating DNA synthesis and cell proliferation in a tonic inhibitory manner. Also binds delta opioid receptors. Intermittent blockade by low-dose naltrexone upregulates receptor expression and endogenous MENK tone.
An endogenous opioid pentapeptide also designated opioid growth factor (OGF). Studied for immune modulation, autoimmune disease, and as a complement to low-dose naltrexone (LDN) protocols.
Research Areas
immune modulationcell proliferation regulationanti-inflammatoryautoimmune support
Regulatory & Evidence
Risk Profile
Medium Risk
Moderate risk profile in research contexts. Review contraindications and administration guidelines before use.
Regulatory Status
- Availability Status
- Research Only
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.